Evaluation of efficacy and safety of the first inhibitor of If-receptors ivabradin (Coraxan) use in the patient suffering ischemic heart disease and broncho-obstructive syndrome
We have demonstrated experience in the use of a new If-receptor inhibitor ivabradine (Koraksan) in patient suffering from respiratory failure with the formation of pulmonary heart that has developed secondary to combination of chronic obstructive pulmonary disease and asthma, as well as hypertension and coronary artery disease with a relative contraindication to the recommended standard therapy CHD administration. Due to the lack of efficacy of Nebilet at daily dose of 5 mg that has manifested a tendency to tachycardia in the daytime and night-time, Koraksan was added to treatment at daily dose of 7.5 mg. We noted the high efficiency and safety of this treatment regimen after 12 months of therapy. Heart rate was decreased significantly, and exercise tolerance increase was registered.

Keywords: If-receptor inhibitors, sinus tachycardia, chronic ischemic heart disease, ivabradin, chronic obstructive pulmonary disease